BioWorld

March 20, 2009

Cortex Slashing Half its Staff in Latest Round of Belt-Tightening

Cortex Pharmaceuticals Inc. is cutting about half its staff, slashing executive salaries and putting some research projects on the back burner, all in an effort to stay afloat in the troubled economy. (BioWorld Today) Read More

Genome Scan Studies Hold Promise for Cancer Research

Double-Duty Herceptin Variant Challenges Antibody Dogma

Arthritis: How Will it Impact the Biotech and Med-Tech Markets?

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

FB-7033 demonstrates efficacy in MASH management

BioWorld Science

17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...

Illustration of antibody carrying radioactive isotope

Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

BioWorld Science

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...

Bial-Portela discovers new OX1 receptor antagonists

BioWorld Science

Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...

Dividing cancer cells in the cross hairs

SKL-35501 shows broad antitumor activity in solid tumors

BioWorld Science

Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...